616 related articles for article (PubMed ID: 28572863)
1. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R; Zwergel C; Mai A; Valente S
Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
3. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic agents in combined anticancer therapy.
Kejík Z; Jakubek M; Kaplánek R; Králová J; Mikula I; Martásek P; Král V
Future Med Chem; 2018 May; 10(9):1113-1130. PubMed ID: 29676175
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapies move into new territory, but how exactly do they work?
Tuma RS
J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
[No Abstract] [Full Text] [Related]
6. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
[TBL] [Abstract][Full Text] [Related]
7. DNA methyltransferase inhibitors: an updated patent review (2012-2015).
Xu P; Hu G; Luo C; Liang Z
Expert Opin Ther Pat; 2016 Sep; 26(9):1017-30. PubMed ID: 27376512
[TBL] [Abstract][Full Text] [Related]
8. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
Conte M; De Palma R; Altucci L
Int J Biochem Cell Biol; 2018 May; 98():65-74. PubMed ID: 29535070
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
12. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
Singh D; Khan MA; Siddique HR
Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
14. DNA Methylation-Targeted Drugs.
Da Costa EM; McInnes G; Beaudry A; Raynal NJ
Cancer J; 2017; 23(5):270-276. PubMed ID: 28926427
[TBL] [Abstract][Full Text] [Related]
15. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
16. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
17. New frontiers in oncology: Immune checkpoint inhibitors in combination therapy.
Romano G; Gawlinski A
Drugs Today (Barc); 2017 Feb; 53(2):103-115. PubMed ID: 28387388
[TBL] [Abstract][Full Text] [Related]
18. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
Bruyer A; Maes K; Herviou L; Kassambara A; Seckinger A; Cartron G; Rème T; Robert N; Requirand G; Boireau S; Müller-Tidow C; Veyrune JL; Vincent L; Bouhya S; Goldschmidt H; Vanderkerken K; Hose D; Klein B; De Bruyne E; Moreaux J
Br J Cancer; 2018 Apr; 118(8):1062-1073. PubMed ID: 29500406
[TBL] [Abstract][Full Text] [Related]
19. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application.
Hu C; Liu X; Zeng Y; Liu J; Wu F
Clin Epigenetics; 2021 Aug; 13(1):166. PubMed ID: 34452630
[TBL] [Abstract][Full Text] [Related]
20. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
